# Avalyn Pharma Inc. Common Stock (AVLN)

> Avalyn Pharma Inc. Common Stock (AVLN) trades at $28.09 (+0.61%) as of 4:20:48 PM EST on Nov 18, 2026, +12.42% over the past month. Market cap is $1.23B, with 5.3 days to cover in short interest.

Canonical: https://massive.com/quote/avln
Data as of: 2026-11-18T21:20:48.030Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$28.09** +0.17 (+0.61%)
As of 4:20:48 PM EST on Nov 18, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Avalyn Pharma Inc. Common Stock (AVLN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -0.82% |
| 1W | -12.43% |
| 1M | +12.42% |
| YTD | -6.10% |
| 1Y | -6.10% |
| 52-wk range | $22.24 – $40.17 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for AVLN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $27.29 – $29.08 |
| Open | $27.74 |
| Prev close | $27.92 |
| Volume | 404.89K |
| Market cap | $1.23B |
| Shares out | 44.52M |

## Valuation and profitability ratios

Valuation and profitability ratios for Avalyn Pharma Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 3.33 |
| P/FCF | — |
| ROE | -29.4% |
| ROA | -27.3% |
| Debt/Equity | 0.04 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Avalyn Pharma Inc. Common Stock (AVLN) insider trading](https://massive.com/quote/avln/insider-trading.md): open-market Form 4 buys and sells by Avalyn Pharma Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Avalyn Pharma Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Avalyn Pharma Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026.”
- Sep 16, 2026 · Executive compensation change
  “Under the Company's Non-Employee Director Compensation Policy (the "Compensation Policy"), Dr. Meyer is eligible to receive an annual retainer of $40,000 for serving on the Board. In addition, under the Compensation Policy, on the Effective Date, Dr. Meyer was granted an option to purchase 31,182 shares of the Company's common stock.”
- Jul 1, 2026 · Lease agreement
  “On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to the Sublease providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston, Massachusetts. Pursuant to the Sublease Amendment, the Sublandlord and the Company have agreed to an expansion of the Premises from approximately 8,774 rentable square feet to approximately 13,708 rentable square feet as of the Effective Date. The Company's future minimum lease payments will increase by approximately $924,000 over the remaining lease term.”
- May 1, 2026 · Charter amendment
  “The Company filed an amended and restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware...to, among other things: (i) authorize 700,000,000 shares of common stock, including 500,000,000 shares of voting common stock and 200,000,000 shares of non-voting common stock; (ii) eliminate all references to the previously-existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock.”

## Dividend history and stock splits

Avalyn Pharma Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-3 · Sep 25, 2007

## AVLN short interest

How heavily AVLN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 5.3 |
| Short interest | 2.3M |
| Avg volume | 434.32K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## AVLN news

The latest news and headlines about Avalyn Pharma Inc. Common Stock (AVLN).

- [Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026](https://www.globenewswire.com/news-release/2026/08/24/3350091/0/en/avalyn-announces-multiple-presentations-at-the-european-respiratory-society-international-congress-2026.html) · GlobeNewswire Inc. · Aug 24, 2026 · positive sentiment
- [Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis](https://www.globenewswire.com/news-release/2026/06/17/3313361/0/en/Avalyn-Completes-Target-Enrollment-in-Phase-2b-MIST-Trial-of-AP01-Inhaled-Pirfenidone-for-Patients-with-Progressive-Pulmonary-Fibrosis.html) · GlobeNewswire Inc. · Jun 17, 2026 · positive sentiment
- [Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://www.globenewswire.com/news-release/2026/06/03/3305895/0/en/Avalyn-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html) · GlobeNewswire Inc. · Jun 3, 2026 · positive sentiment

## About Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $18.00 on Apr 30, 2026 |

[Avalyn Pharma IPO page](https://massive.com/quote/avln/ipo.md)

[Company website](https://www.avalynpharma.com)

## FAQ

### What is the Avalyn Pharma Inc. Common Stock (AVLN) stock price today?

Avalyn Pharma Inc. Common Stock (AVLN) is trading at $28.09 (+0.61% on the day) as of 4:20:48 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Avalyn Pharma Inc. Common Stock?

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs).

### What is the short interest in AVLN?

As of Oct 30, 2026, AVLN has 2.3M shares short and 5.3 days to cover.

### What exchange is AVLN listed on?

Avalyn Pharma Inc. Common Stock (AVLN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time AVLN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AVLN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Avalyn Pharma Inc. Common Stock (AVLN) insider trading](https://massive.com/quote/avln/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
